Home Latest News Family Fitness Nutrition Healthy Aging Mental Health
Live Markets
Loading markets...
Covid

Catching Dysgeusia after a COVID-19 Infection

Thumbnail
By Josh Piers - June 06, 2022 - 5 Mins Read
covid19DysgeusiaPaxlovid
Thumbnail
Josh Piers

Related posts

a woman in a pink sweater with her hands on her chest
NB.1.8.1 'Nimbus' Variant Dominates 2026 Winter Surge: Why This 'Razor Blade' Sore Throat is Different
January 19, 2026
a woman in a pink sweater with her hands on her chest
The ‘Razor Blade’ Throat: New ‘Nimbus’ COVID Variant NB.1.8.1 Dominates 2026 Winter Surge
January 19, 2026
a person holding a sign that says if vaccines work who needs segre
19 States Defy CDC Vaccine Overhaul as 'Nimbus' Variant Surge Grips Nation
January 18, 2026
clear glass bottle with orange and green liquid inside
19 States Defy CDC 2026 Vaccine Schedule Over COVID-19 Removal
January 18, 2026

Recent Posts

Editors Picks

Medicare GLP-1 Bridge: $50 Wegovy & Zepbound Copays Healthy Aging
Medicare GLP-1 Bridge: $50 Wegovy & Zepbound Copays
By Dewey Olson - July 10, 2026 - 5 Mins Read
The Medicare GLP-1 Bridge program offers affordable weight loss drugs like Wegovy and Zepbound to eligible seniors for a $50 monthly copay.
Parental Phone Addiction Linked to Teen Anxiety by New Study Family
Parental Phone Addiction Linked to Teen Anxiety by New Study
By Dewey Olson - July 09, 2026 - 5 Mins Read
A groundbreaking July 2026 study reveals that parental phone distraction drives adolescent anxiety, leaving teens feeling dismissed and devalued.
Exercise for Brain Rot: Workouts Protect Memory From Doomscrolling Fitness
Exercise for Brain Rot: Workouts Protect Memory From Doomscrolling
By Brennan Forrest - July 08, 2026 - 5 Mins Read
A new July 2026 study reveals that regular exercise protects your working memory and reverses cognitive fatigue caused by endless video scrolling.
FDA-Bound Psilocybin Therapy Shows Lasting Relief for Depression Mental health
FDA-Bound Psilocybin Therapy Shows Lasting Relief for Depression
By Christian Webster - July 07, 2026 - 5 Mins Read
Compass Pathways reveals landmark 26-week data from its COMP360 Phase 3 trial, bringing a breakthrough psilocybin therapy closer to FDA approval.